A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Study Summary

The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).

Conditions

Metastatic Castration-resistant Prostate Neoplasms Metastatic Hormone-sensitive Prostate Cancer

Interventions / Drugs

Pasritamig Cetrelimab Cabazitaxel Docetaxel Apalutamide Enzalutamide Darolutamide Abiraterone acetate plus prednisone (AAP)Lutetium Lu-177 vipivotide tetraxetan JNJ-101556143

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment300 participants

Primary Completion—

Lead SponsorJanssen Research & Development, LLC

Data Retrieved2026-04-11 02:55:31.550873+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.